Orchestra BioMed Announces Proposed Public Offering
Key Highlights
- ➤Orchestra BioMed commenced an underwritten public offering of common stock.
- ➤Underwriters may purchase up to an additional 15% of shares sold.
- ➤Offering size, pricing, terms, and completion timing remain undetermined.
- ➤Proceeds will fund AVIM Therapy and the BACKBEAT global pivotal trial.
- ➤Proceeds will fund Virtue SAB and the Virtue Trial.
NEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies, announced today that it has commenced an underwritten public offering of shares of its common stock (the “Offering”). All of the securities are being offered by the Company. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of shares of its common stock sold in the Offering at the public offering price per share, less underwriting discounts and commissions. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.
Get started
Create a free account to read the full story.